New clinical guidelines for diabetes
Monday, 10 August 2020
Have your say on the new clinical guidelines for diabetes.
The Living Evidence for Diabetes Consortium is a collaboration between the Australian Diabetes Society (ADS), Diabetes Australia, the Australian Diabetes Educators Association (ADEA) and the Australasian Paediatric Endocrine Group (APEG), with representation from the Royal Australian College of General Practitioners (RACGP), the Australian Government Department of Health and Cochrane Australia.
The Consortium has developed evidence based clinical guidelines for diabetes containing selected recommendations regarding:
- Medical device technology for the management of type 1 diabetes; and
- Medications for blood glucose management in adults with type 2 diabetes.
The Consortium is inviting comment from interested parties on the guidelines.
Invitation to comment
The Living Evidence for Diabetes Consortium is seeking NHMRC approval of the guideline under section 14A of the National Health and Medical Research Council Act 1992. As part of the approval process and to improve the recommendations, we encourage you to review the guideline and provide feedback.
About the consultation
Public consultation will run from Wednesday 5th August to Friday 4th September 2020. Late submissions will not be accepted.
The guideline can be found here.
How to respond
Submissions may include identified issues, suggested improvements, or whether or not you support the recommendations. If you do not support the recommendation(s),
please provide reasons and propose suitable amendments.
Comments can be submitted via the feedback function under each recommendation within MAGICapp or via email at email@example.com. The Consortium will consider all comments received, and a summary of submissions and the actions taken will be provided following consultation.